Search Results - "ROTMENSCH, Jacob"

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study by AGHAJANIAN, Carol, SILL, Michael W, DARCY, Kathleen M, GREER, Benjamin, SCOTT MCMEEKIN, D, ROSE, Peter G, ROTMENSCH, Jacob, BARNES, Mack N, HANJANI, Parviz, LESLIE, Kimberly K

“…Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types…”
Get full text

Quality of Life of Patients With Endometrial Cancer Undergoing Laparoscopic International Federation of Gynecology and Obstetrics Staging Compared With Laparotomy: A Gynecologic Oncology Group Study by KORNBLITH, Alice B, HUANG, Helen Q, WALKER, Joan L, SPIRTOS, Nick M, ROTMENSCH, Jacob, CELLA, David

“…The study's objective was to compare the quality of life (QoL) of patients with endometrial cancer undergoing surgical staging via laparoscopy versus…”
Get full text

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study by Alvarez, Edwin A, Brady, William E, Walker, Joan L, Rotmensch, Jacob, Zhou, Xun C, Kendrick, James E, Yamada, S. Diane, Schilder, Jeanne M, Cohn, David E, Harrison, Charles R, Moore, Kathleen N, Aghajanian, Carol

“…Abstract Objective This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with…”
Get full text

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study by Coleman, Robert L, Sill, Michael W, Thaker, Premal H, Bender, David P, Street, Daron, McGuire, William P, Johnston, Carolyn M, Rotmensch, Jacob

“…Abstract Background Activation of the mitogen activated protein kinase pathway plays a pivotal role in cell proliferation and is frequently activated in…”
Get full text

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? by Mitchell, Rachel, Buckingham, Lela, Cobleigh, Melody, Rotmensch, Jacob, Burgess, Kelly, Usha, Lydia

“…Hereditary breast and ovarian cancer syndrome (HBOC) is most frequently caused by mutations in BRCA1 or BRCA2 (in short, BRCA) genes. The incidence of…”
Get full text

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications by Sutaria, Dhruvitkumar S., Agarwal, Priya, Huang, Kuan‐Chieh, Miles, Dale R., Rotmensch, Jacob, Hinton, Heather, Gallo, Jorge Daniel, Rasuo, Grozdana, Sane, Rucha S.

“…Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant…”
Get full text

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study by Campos, Susana M, Brady, William E, Moxley, Katherine M, O'Cearbhaill, Roisin E, Lee, Paula S, DiSilvestro, Paul A, Rotmensch, Jacob, Rose, Peter G, Thaker, Premal H, O'Malley, David M, Hanjani, Parviz, Zuna, Rosemary E, Hensley, Martee L

“…Abstract Objective Carcinosarcomas of the female genital tract, also called malignant mixed müllerian tumors, are aggressive biphasic tumors. Second-line…”
Get full text

Optimal surgical debulking in uterine papillary serous carcinoma affects survival by Patsavas, Kristia, Woessner, Jessica, Gielda, Benjamin, Rotmensch, Jacob, Yordan, Edgardo, Bitterman, Pincas, Guirguis, Alfred

“…Abstract Objective UPSC is similar to papillary serous ovarian carcinoma in its histology and pattern of spread. The survival advantage with optimal debulking…”
Get full text

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study by Duska, Linda R, Blessing, John A, Rotmensch, Jacob, Mannel, Robert S, Hanjani, Parviz, Rose, Peter G, Dizon, Don S

“…Abstract Objective The combination of gemcitabine and docetaxel is the standard first-line therapy for recurrent or metastatic uterine leiomyosarcoma. There is…”
Get full text

Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy by Lujan, Anthony E, Mundt, Arno J, Yamada, S Diane, Rotmensch, Jacob, Roeske, John C

“…To evaluate intensity-modulated whole pelvis radiotherapy (IM-WPRT) (with bone marrow [BM] as a planning constraint) as a means to reduce the volume of pelvic…”
Get more information

Somatic variants of potential clinical significance in the tumors of BRCA phenocopies by Buckingham, Lela, Mitchell, Rachel, Maienschein-Cline, Mark, Green, Stefan, Hu, Vincent Hong, Cobleigh, Melody, Rotmensch, Jacob, Burgess, Kelly, Usha, Lydia

“…phenocopies are individuals with the same phenotype (i.e. cancer consistent with Hereditary Breast and Ovarian Cancer syndrome = HBOC) as their affected…”
Get full text

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study by Tait, David L, Blessing, John A, Hoffman, James S, Moore, Kathleen N, Spirtos, Nick M, Lachance, Jason A, Rotmensch, Jacob, Miller, David S

“…Abstract Objective The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial…”
Get full text

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study by Aghajanian, Carol, Blessing, John A, Darcy, Kathleen M, Reid, Gary, DeGeest, Koen, Rubin, Stephen C, Mannel, Robert S, Rotmensch, Jacob, Schilder, Russell J, Riordan, William

“…Abstract Objective To determine the activity and pharmacodynamics (PD) of bortezomib in platinum-sensitive epithelial ovarian or primary peritoneal cancer…”
Get full text

Evaluation of Pulmonary Complications in Robotic-Assisted Gynecologic Surgery by Burks, Channing, MD, Nelson, Lia, MD, Kumar, Daveshni, MD, Fogg, Louis, PhD, Saha, Chiiranjeev, MD, Guirguis, Alfred, DO, Rotmensch, Jacob, MD, Dewdney, Summer, MD

“…Abstract Study Objective To conduct a study to assess the incidence of pulmonary complications associated with robotic-assisted surgeries in women with various…”
Get full text

Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells by Li, Liang-Cheng, PhD, Jayaram, Shankar, PhD, Ganesh, Lakshmy, MS, Qian, Lixia, BS, Rotmensch, Jacob, MD, Maker, Ajay V., MD, Prabhakar, Bellur S., PhD

“…Objective The clinical utility of tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) in the treatment of established human malignancies is limited…”
Get full text

Immunohistochemical Characterization of Squamous Differentiation and Morular Metaplasia in Uterine Endometrioid Adenocarcinoma by Blanco, Luis Z, Heagley, Dawn E, Lee, John C, Gown, Allen M, Gattuso, Paolo, Rotmensch, Jacob, Guirguis, Alfred, Dewdney, Summer, Bitterman, Pincas

“…Squamous differentiation (SD) and morular metaplasia (MM) are frequently present in uterine endometrioid adenocarcinoma (EAC) and can mimic areas of solid…”
Get full text

Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy by Murphy, Kevin T, Rotmensch, Jacob, Yamada, S Diane, Mundt, Arno J

“…To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT)…”
Get more information

Helical Tomotherapy Delivery of an IMRT Boost in Lieu of Interstitial Brachytherapy in the Setting of Gynecologic Malignancy: Feasibility and Dosimetric Comparison by Gielda, Benjamin T., M.D, Shah, Anand P., M.D, Marsh, James C., M.D, Smart, Joseph P., (R.)T.T, Bernard, Damian, Ph.D, Rotmensch, Jacob, M.D, Griem, Katherine L., M.D., F.A.C.R

“…Abstract Interstitial brachytherapy is an important means by which to improve local control in gynecologic malignancy when intracavitary brachytherapy is…”
Get full text

Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study by Edmonson, John H., Blessing, John A., Cosin, Jonathan A., Miller, David Scott, Cohn, David E., Rotmensch, Jacob

“…Objective. Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic…”
Get full text

A dosimetric comparison of Xoft Axxent Electronic Brachytherapy™ and Ir-192 HDR brachytherapy in the treatment of endometrial cancer by Dickler, Adam, M.D, Kirk, Michael C., Ph.D, Coon, Alan, M.D, Bernard, Damian, Ph.D, Rotmensch, Jacob, M.D, Zusag, Thomas W., M.D

Get full text